A Novel CNS-Targeted Non-Opioid Analgesic Platform
Faster relief. Fewer risks. A new standard for pain and fever management.
The Opportunity
A $1–$3B U.S. market with unmet needs in speed, safety, and route of administration
$1–$3 Billion U.S. Market
Realistic obtainable share of $200–300M/year with unprecedented segmentation for ultra-fast and breakthrough pain relief.
Non-Opioid Modality
Addresses the growing clinical need for effective non-opioid analgesics amid the ongoing opioid crisis.
Ultra-Fast Onset
Direct-to-brain delivery bypasses first-pass metabolism, enabling faster onset than oral or rectal routes.
OTC Upside
505(b)(2) pathway targets direct-to-OTC status — the largest commercial opportunity in the program.
The Clinical Gap: Why Intranasal?
Existing analgesic routes carry inherent limitations — a better path exists through the nose
Oral
- ~ 60 to 90 minute onset
- Hepatic first-pass metabolism
- Dose-limited by hepatotoxicity risk
- Difficult in pediatric / nauseous patients
IV / Rectal
- IV has faster onset
- Invasive or inconvenient
- Requires healthcare setting
- Poor patient acceptance
Our Approach
Direct to Brain—Intranasal
- Ultra-fast CNS delivery via olfactory pathway
- Fastest onset and peak effect 10 to 15 minutes – faster than IV
- Bypasses hepatic first-pass
- Lower effective dose potential
- Patient self-administered
Value Propositions
Clinical, commercial, and regulatory advantages converge in a single platform
Ultra-Fast Pain & Fever Relief
Onset potentially faster than oral or rectal routes — addressing breakthrough pain and high-acuity fever in adults and children.
Improved Safety Profile
Potential for lower effective doses with reduced hepatotoxicity risk. Favorable nasal safety profile is expected and supports the OTC pathway.
Non-Opioid Treatment Modality
Directly addresses opioid crisis demand. FDA environment is favorable; no opioid risk means a cleaner regulatory narrative.
Formulation & Device Innovation
Formulations paired with a specialized posterior nasal device — enabling effective olfactory delivery.
Regulatory Strategy
505(b)(2) pathway leveraging existing the safety record — targeting non-prescription status